6-p-Dimethylaminophenylazobenzothiazole: a potent hepatocarcinogen in the rat.
6-p-Dimethylaminophenylazobenzothiazole (6BT) administered at a dose of 10 mg/kg by gavage to Sprague-Dawley and Wistar-derived rats for 2 months produced marked cellular changes in the liver, including proliferation of oval cells and the formation of regenerative/hyperplastic nodules. Cellular change continued after stopping dosing at 2 months such that liver tumours were first observed after only 4 months into the study, and animals examined between 4 months and termination at 6 months showed a 75% and 85% incidence of hepatocellular carcinoma for the Sprague-Dawley and Wistar strains, respectively. This study establishes 6BT as a potent hepatocarcinogen in the rat when administered by gavage, and confirms and extends an initial brief report by Brown and Sanchorawala in 1968 of its carcinogenicity following dietary administration.
D000818:Animals; D052160:Benzothiazoles; D002273:Carcinogens / Q000633:toxicity*; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D013844:Thiazoles / Q000633:toxicity*; D004124:p-Dimethylaminoazobenzene / Q000031:analogs & derivatives* / Q000633:toxicity
D052160:Benzothiazoles; D002273:Carcinogens; D013844:Thiazoles; C012103:N,N-dimethyl-4-(6-benzothiazolylazo)aniline; D004124:p-Dimethylaminoazobenzene